About Genpharmasec
Genpharmasec is a publicly listed company. Pharmaceutical products and services are provided and distributed. The company has 10 employees. Its Indian entity Genpharmasec Limited reported revenue of ₹143 Cr. Genpharmasec offers products and services including Pharmaceutical Products and Compliance Services. Its focus areas include Traditional Pharmaceuticals.
Company details
Genpharmasec was incorporated in 1992 as a public limited company within the pharmaceutical sector. Operations are centered on the development and distribution of pharmaceutical products, with efforts directed toward expanding the product portfolio and increasing trade. The company is overseen by a team of experienced executives, including a designated Company Secretary and Compliance Officer. Focus remains on core pharmaceutical services without specified geographic limitations.
- Employees 10
- Stage Public
- SectorsHealthcare
- Website genpharmasec.com
- Legal Name Genpharmasec Limited
- Market Cap₹59.80 Cr
GENPHARMA · BSE
- Share Price₹1.05
-2.78% today
- Revenue₹140 Cr
FY 2025-26 · +315.0% YoY
- EBITDA₹1.22 Cr
Margin 0.9%
- Net Profit₹1.60 Cr
FY 2025-26 · +31.2% YoY
- P/E (TTM)27.6x
P/B 0.9x
- ROE0.8%
ROCE 2.5%
- Debt / Equity0.31
Interest cover -129.2x
- Employee Count10
Associated legal entities of Genpharmasec
Genpharmasec operates through Genpharmasec Limited, a listed company (active). Its filings, financials, charges and directors are on the company page.
| Legal entity | Status | Incorporated | Registered in | Revenue (FY 2026) | Employees | Directors | Company page |
|---|---|---|---|---|---|---|---|
| Genpharmasec Limited Listed CIN L24231MH1992PLC323914 | Active | 16 Nov 1992 | Mumbai, Maharashtra | ₹143 Cr | 9 | View details |
Products & Services of Genpharmasec
Genpharmasec offers a comprehensive portfolio of products and services, including Pharmaceutical Products and Compliance Services.
Pharmaceutical products are manufactured and managed as part of the company's operations.
Compliance and management services are provided to support business activities.
Board of directors of Genpharmasec Limited (Genpharmasec)
Genpharmasec Limited is the primary company behind Genpharmasec. The board of Genpharmasec Limited currently have 7 directors; the longest-serving is Rajesh Mirchumal Sadhwani, appointed in 2019. 20 earlier directors have ceased.
| Director | Designation | Appointed | Tenure | Entity |
|---|---|---|---|---|
| Rajesh Mirchumal Sadhwani DIN 08315182 | Director | 02 Jan 2019 | 7 yrs 10 mo | Genpharmasec Limited |
| Sneha Sadhwani DIN 08315181 | Director | 02 Jan 2019 | 7 yrs 10 mo | Genpharmasec Limited |
| Siddhesh Shankar Shende DIN 09629926 | Director | 04 Jul 2022 | 4 yrs 4 mo | Genpharmasec Limited |
| Mayur Bharatbhai Bhatt DIN 08715614 | Director | 01 Nov 2022 | 4 yrs | Genpharmasec Limited |
| Sachin Prakash Aphandkar DIN 08715329 | Director | 01 Nov 2022 | 4 yrs | Genpharmasec Limited |
| Hardik Pravinbhai Makwana DIN 09103236 | Company Secretary | 27 Mar 2024 | 2 yrs 7 mo | Genpharmasec Limited |
| Sohan Chaturvedi DIN 09629728 | Whole-time director | 26 Apr 2024 | 2 yrs 6 mo | Genpharmasec Limited |
IPO & Listings of Genpharmasec
Genpharmasec is a publicly listed company on the BSE with ticker symbol GENPHARMA in India, operating in the Process industries sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date15 Apr 1996
- Listed onBSE: 531592
- Listed entityGenpharmasec Limited
- Exchange sectorProcess industries
- ISININE861N01036
- Share price₹1.02 (+2% on the day) · 2026-10-14
- Market capitalisation₹55.4 Cr
- Price to earnings137.5
- EPS (diluted, trailing year)₹-0.00
- Volume (last session)163,220
Financials of Genpharmasec
Exchange-reported figures of Genpharmasec Limited, the listed company behind Genpharmasec (BSE: GENPHARMA).
Financial Highlights
FY 2025-26 · ConsolidatedRevenue vs Net Profit ₹ Cr
Margin trends
Financial summary ₹ Cr
| Metrics | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 |
|---|---|---|---|---|
| Income statement | ||||
| Revenue | 140 | 33.72 | 30.41 | 25.52 |
| Revenue growth | +315.0% | +10.9% | +19.2% | - |
| EBITDA | 1.22 | 0.07 | 0.06 | 0.26 |
| EBITDA margin | +0.9% | +0.2% | +0.2% | +1.0% |
| Profit before tax | 0.97 | 1.87 | 0.27 | 0.28 |
| Net profit | 1.60 | 1.22 | (0.15) | 1.12 |
| Net profit margin | +1.1% | +3.6% | -0.5% | +4.4% |
| EPS (₹) | 0.01 | 0.02 | 0.00 | 0.04 |
| Balance sheet | ||||
| Total assets | 101 | 70.57 | 68.42 | 18.41 |
| Net worth | 66.26 | 65.16 | 64.39 | 15.33 |
| Total debt | 34.95 | 5.28 | 3.89 | 3.08 |
| Cash & bank | 10.07 | 5.27 | 18.83 | 1.99 |
| Net working capital | 43.10 | 17.11 | 36.58 | 16.51 |
| Cash flow | ||||
| Cash from operations | (17.55) | 2.95 | (2.95) | (3.06) |
| Cash from investing | 13.26 | (4.22) | (28.06) | 0.36 |
| Cash from financing | 3.92 | (1.25) | 47.85 | 3.08 |
| Particulars | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 85.66 | 49.71 | 55.43 | 39.83 | 32.64 | 12.04 | 14.01 | 8.48 |
| Revenue growth (YoY) | +162.4% | +312.9% | +295.7% | +369.7% | +441.3% | +131.5% | - | - |
| Other income | 1.06 | 0.37 | 1.02 | 0.98 | 0.46 | 0.69 | 0.94 | 0.81 |
| EBITDA | 1.64 | 0.96 | 1.99 | (1.24) | (0.47) | 0.94 | (1.00) | 0.71 |
| EBITDA margin | +1.9% | +1.9% | +3.6% | -3.1% | -1.4% | +7.8% | -7.1% | +8.4% |
| Depreciation | 0.68 | 0.67 | 0.68 | 0.67 | 0.56 | 0.27 | 0.26 | 0.10 |
| Interest | 0.44 | 0.40 | 0.48 | 0.41 | 0.23 | 0.12 | 0.11 | 0.16 |
| Profit before tax | 1.58 | 0.26 | 1.85 | (1.34) | (0.80) | 1.24 | (0.43) | 1.26 |
| Tax | 0.55 | 0.43 | 0.50 | (0.50) | 0.38 | 0.03 | (0.16) | 0.51 |
| Net profit | 1.03 | (0.17) | 1.35 | (0.84) | (1.18) | 1.21 | (0.27) | 0.75 |
| EPS (₹) | 0.01 | 0.00 | 0.02 | (0.02) | (0.02) | 0.02 | (0.01) | 0.01 |
| Metrics | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Income statement | |||||||
| Revenue | 131 | 32.96 | 30.41 | 25.52 | 27.32 | 21.31 | 16.50 |
| Revenue growth | +298.5% | +8.4% | +19.2% | -6.6% | +28.2% | +29.2% | - |
| EBITDA | 2.42 | 0.44 | 0.18 | 0.26 | (0.51) | 1.19 | 0.64 |
| EBITDA margin | +1.8% | +1.3% | +0.6% | +1.0% | -1.9% | +5.6% | +3.9% |
| Profit before tax | 6.44 | 3.45 | 0.49 | 0.28 | (0.43) | 1.51 | 1.20 |
| Net profit | 5.46 | 2.47 | 0.07 | 1.12 | (0.20) | 1.26 | 1.00 |
| Net profit margin | +4.2% | +7.5% | +0.2% | +4.4% | -0.7% | +5.9% | +6.1% |
| EPS (₹) | 0.10 | 0.04 | 0.00 | 0.04 | (0.01) | 0.05 | 0.05 |
| Balance sheet | |||||||
| Total assets | 76.54 | 69.98 | 67.78 | 18.41 | 15.37 | 20.66 | 19.03 |
| Net worth | 71.49 | 66.55 | 64.57 | 15.33 | 15.37 | 20.67 | 19.04 |
| Total debt | 4.98 | 3.43 | 3.21 | 3.08 | 0.00 | 0.00 | 0.00 |
| Cash & bank | 9.29 | 5.14 | 18.58 | 1.99 | 1.61 | 3.53 | 2.58 |
| Net working capital | 28.27 | 17.82 | 35.65 | 16.51 | 12.82 | 11.95 | 7.87 |
| Cash flow | |||||||
| Cash from operations | 1.93 | 0.96 | (2.27) | (3.06) | (2.34) | (2.13) | 1.39 |
| Cash from investing | (1.64) | (2.92) | (29.03) | 0.36 | 0.42 | (1.41) | (4.01) |
| Cash from financing | (0.02) | (0.44) | 47.89 | 3.08 | 0.00 | 4.50 | 0.00 |
| Particulars | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 50.83 | 44.78 | 51.66 | 36.01 | 31.56 | 12.11 | 13.56 | 8.34 |
| Revenue growth (YoY) | +61.1% | +269.8% | +281.0% | +331.8% | +447.0% | +128.5% | - | - |
| Other income | 1.66 | 0.97 | 1.62 | 1.43 | 1.00 | 0.82 | 1.06 | 0.93 |
| Total expenses | 49.18 | 43.43 | 50.08 | 36.68 | 31.06 | 11.11 | 14.55 | 7.40 |
| EBITDA | 1.65 | 1.35 | 1.58 | (0.67) | 0.50 | 1.00 | (0.99) | 0.94 |
| EBITDA margin | +3.2% | +3.0% | +3.1% | -1.9% | +1.6% | +8.3% | -7.3% | +11.3% |
| Depreciation | 0.10 | 0.10 | 0.09 | 0.07 | 0.04 | 0.04 | 0.04 | 0.05 |
| Interest | 0.16 | 0.13 | 0.25 | 0.19 | 0.08 | 0.08 | 0.06 | 0.11 |
| Profit before tax | 3.05 | 2.09 | 2.86 | 0.50 | 1.38 | 1.70 | (0.03) | 1.71 |
| Tax | 0.49 | 0.53 | 0.55 | (0.27) | 0.57 | 0.15 | 0.20 | 0.61 |
Financial Statements
| Particulars | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 85.66 | 49.71 | 55.43 | 39.83 | 32.64 | 12.04 | 14.01 | 8.48 |
| Revenue growth (YoY) | +162.4% | +312.9% | +295.7% | +369.7% | +441.3% | +131.5% | - | - |
| Other income | 1.06 | 0.37 | 1.02 | 0.98 | 0.46 | 0.69 | 0.94 | 0.81 |
| EBITDA | 1.64 | 0.96 | 1.99 | (1.24) | (0.47) | 0.94 | (1.00) | 0.71 |
| EBITDA margin | +1.9% | +1.9% | +3.6% | -3.1% | -1.4% | +7.8% | -7.1% | +8.4% |
| Depreciation | 0.68 | 0.67 | 0.68 | 0.67 | 0.56 | 0.27 | 0.26 | 0.10 |
| Interest | 0.44 | 0.40 | 0.48 | 0.41 | 0.23 | 0.12 | 0.11 | 0.16 |
| Profit before tax | 1.58 | 0.26 | 1.85 | (1.34) | (0.80) | 1.24 | (0.43) | 1.26 |
| Tax | 0.55 | 0.43 | 0.50 | (0.50) | 0.38 | 0.03 | (0.16) | 0.51 |
| Net profit | 1.03 | (0.17) | 1.35 | (0.84) | (1.18) | 1.21 | (0.27) | 0.75 |
| EPS (₹) | 0.01 | 0.00 | 0.02 | (0.02) | (0.02) | 0.02 | (0.01) | 0.01 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 |
|---|---|---|---|---|
| Revenue | 140 | 33.72 | 30.41 | 25.52 |
| Revenue growth | +315.0% | +10.9% | +19.2% | - |
| Other income | 3.16 | 3.06 | 0.66 | 0.10 |
| Total expenses | 139 | 33.65 | 30.35 | 25.26 |
| Employee cost | 0.00 | 0.99 | 0.76 | 0.54 |
| EBITDA | 1.22 | 0.07 | 0.06 | 0.26 |
| EBITDA margin | +0.9% | +0.2% | +0.2% | +1.0% |
| Depreciation | 2.17 | 0.81 | 0.04 | 0.02 |
| Interest | 1.24 | 0.45 | 0.41 | 0.06 |
| Profit before tax | 0.97 | 1.87 | 0.27 | 0.28 |
| Tax | 0.41 | 0.65 | 0.42 | (0.84) |
| Net profit | 1.60 | 1.22 | (0.15) | 1.12 |
| Net profit margin | +1.1% | +3.6% | -0.5% | +4.4% |
| EPS (₹) | 0.01 | 0.02 | 0.00 | 0.04 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 |
|---|---|---|---|---|
| Equity & liabilities | ||||
| Share capital | 55.37 | 55.37 | 55.37 | 27.69 |
| Reserves & surplus | 10.89 | 9.79 | 9.02 | (12.36) |
| Shareholders' funds (net worth) | 66.26 | 65.16 | 64.39 | 15.33 |
| Minority interest | (0.62) | 0.12 | 0.14 | 0.00 |
| Secured loans | 1.08 | 0.00 | 0.00 | 0.00 |
| Unsecured loans | 33.87 | 5.28 | 3.89 | 3.08 |
| Total debt | 34.95 | 5.28 | 3.89 | 3.08 |
| Total liabilities | 101 | 70.57 | 68.42 | 18.41 |
| Assets | ||||
| Gross block | 47.84 | 8.48 | 0.93 | 0.15 |
| Net block | 41.25 | 7.59 | 0.83 | 0.10 |
| Capital work in progress | 0.00 | 0.00 | 0.00 | 0.00 |
| Investments | 1.58 | 19.73 | 19.32 | 0.95 |
| Inventories | 13.88 | 7.30 | 8.84 | 9.68 |
| Sundry debtors | 29.27 | 13.60 | 9.10 | 5.71 |
| Cash & bank balances | 10.07 | 5.27 | 18.83 | 1.99 |
| Loans & advances | 27.30 | 0.25 | 2.51 | 0.59 |
| Total current assets | 80.52 | 26.42 | 39.28 | 17.97 |
| Total current liabilities | 37.42 | 9.31 | 2.70 | 1.46 |
| Net working capital | 43.10 | 17.11 | 36.58 | 16.51 |
| Total assets | 101 | 70.57 | 68.42 | 18.41 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 |
|---|---|---|---|---|
| Opening cash | 1.34 | 3.17 | 1.99 | 1.61 |
| Net cash from operating activities | (17.55) | 2.95 | (2.95) | (3.06) |
| Net cash from investing activities | 13.26 | (4.22) | (28.06) | 0.36 |
| Net cash from financing activities | 3.92 | (1.25) | 47.85 | 3.08 |
| Net change in cash | (0.37) | (2.52) | 16.84 | 0.39 |
| Closing cash | 10.07 | 5.27 | 18.83 | 1.99 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 |
|---|---|---|---|---|
| Growth | ||||
| Sales growth | +315.0% | +10.9% | +19.2% | - |
| EBITDA growth | +1642.9% | +16.7% | -76.9% | - |
| PBT growth | -56.8% | +722.2% | -3.6% | +9997.0% |
| Net income growth | +31.2% | +913.3% | -113.4% | - |
| Revenue CAGR (3Y) | +76.3% | - | - | - |
| EBITDA CAGR (3Y) | +67.0% | - | - | - |
| Profitability & leverage | ||||
| Net income margin | +0.4% | +4.7% | -0.5% | +4.4% |
| Return on capital employed | +2.5% | +3.7% | 0.0% | +1.5% |
| Return on net worth | +0.8% | +2.4% | 0.0% | +5.6% |
| Debt / equity | 0.31 | 0.07 | 0.09 | 0.20 |
| Long-term debt / equity | 0.23 | 0.07 | 0.08 | 0.16 |
| Interest cover | -129.17 | -104.88 | 2,050.00 | 25.00 |
| Efficiency & per share | ||||
| Fixed asset turnover | 4.97 | 7.17 | 56.31 | 170.13 |
| Inventory turnover | 13.21 | 4.18 | 3.28 | 2.64 |
| Debtors turnover | 6.53 | 2.97 | 4.11 | 4.47 |
| EPS (₹) | 0.03 | 0.03 | 0.00 | 0.04 |
| Dividend per share (₹) | 0.00 | 0.00 | 0.00 | 0.00 |
| Book value per share (₹) | 1.20 | 1.18 | 1.16 | 0.55 |
| Particulars | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 50.83 | 44.78 | 51.66 | 36.01 | 31.56 | 12.11 | 13.56 | 8.34 |
| Revenue growth (YoY) | +61.1% | +269.8% | +281.0% | +331.8% | +447.0% | +128.5% | - | - |
| Other income | 1.66 | 0.97 | 1.62 | 1.43 | 1.00 | 0.82 | 1.06 | 0.93 |
| Total expenses | 49.18 | 43.43 | 50.08 | 36.68 | 31.06 | 11.11 | 14.55 | 7.40 |
| EBITDA | 1.65 | 1.35 | 1.58 | (0.67) | 0.50 | 1.00 | (0.99) | 0.94 |
| EBITDA margin | +3.2% | +3.0% | +3.1% | -1.9% | +1.6% | +8.3% | -7.3% | +11.3% |
| Depreciation | 0.10 | 0.10 | 0.09 | 0.07 | 0.04 | 0.04 | 0.04 | 0.05 |
| Interest | 0.16 | 0.13 | 0.25 | 0.19 | 0.08 | 0.08 | 0.06 | 0.11 |
| Profit before tax | 3.05 | 2.09 | 2.86 | 0.50 | 1.38 | 1.70 | (0.03) | 1.71 |
| Tax | 0.49 | 0.53 | 0.55 | (0.27) | 0.57 | 0.15 | 0.20 | 0.61 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Revenue | 131 | 32.96 | 30.41 | 25.52 | 27.32 | 21.31 | 16.50 |
| Revenue growth | +298.5% | +8.4% | +19.2% | -6.6% | +28.2% | +29.2% | - |
| Other income | 4.87 | 3.43 | 0.72 | 0.10 | 0.09 | 0.33 | 0.56 |
| Total expenses | 129 | 32.52 | 30.23 | 25.26 | 27.83 | 20.12 | 15.86 |
| Employee cost | 0.00 | 0.67 | 0.76 | 0.54 | 0.25 | 0.19 | 0.13 |
| EBITDA | 2.42 | 0.44 | 0.18 | 0.26 | (0.51) | 1.19 | 0.64 |
| EBITDA margin | +1.8% | +1.3% | +0.6% | +1.0% | -1.9% | +5.6% | +3.9% |
| Depreciation | 0.26 | 0.13 | 0.02 | 0.02 | 0.01 | 0.01 | 0.00 |
| Interest | 0.59 | 0.29 | 0.39 | 0.06 | 0.00 | 0.00 | 0.00 |
| Profit before tax | 6.44 | 3.45 | 0.49 | 0.28 | (0.43) | 1.51 | 1.20 |
| Tax | 0.98 | 0.98 | 0.42 | (0.84) | (0.23) | 0.25 | 0.20 |
| Net profit | 5.46 | 2.47 | 0.07 | 1.12 | (0.20) | 1.26 | 1.00 |
| Net profit margin | +4.2% | +7.5% | +0.2% | +4.4% | -0.7% | +5.9% | +6.1% |
| EPS (₹) | 0.10 | 0.04 | 0.00 | 0.04 | (0.01) | 0.05 | 0.05 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Equity & liabilities | |||||||
| Share capital | 55.37 | 55.37 | 55.37 | 27.69 | 27.69 | 27.69 | 21.69 |
| Reserves & surplus | 16.12 | 11.18 | 9.20 | (12.36) | (12.32) | (7.02) | (4.15) |
| Shareholders' funds (net worth) | 71.49 | 66.55 | 64.57 | 15.33 | 15.37 | 20.67 | 19.04 |
| Secured loans | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Unsecured loans | 4.98 | 3.43 | 3.21 | 3.08 | 0.00 | 0.00 | 0.00 |
| Total debt | 4.98 | 3.43 | 3.21 | 3.08 | 0.00 | 0.00 | 0.00 |
| Total liabilities | 76.54 | 69.98 | 67.78 | 18.41 | 15.37 | 20.66 | 19.03 |
| Assets | |||||||
| Gross block | 1.24 | 0.45 | 0.17 | 0.15 | 0.14 | 0.07 | 0.05 |
| Net block | 1.13 | 0.36 | 0.10 | 0.10 | 0.11 | 0.05 | 0.04 |
| Capital work in progress | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Investments | 21.67 | 20.84 | 19.52 | 0.95 | 2.45 | 7.81 | 5.76 |
| Inventories | 12.58 | 7.24 | 8.84 | 9.68 | 9.89 | 7.68 | 3.46 |
| Sundry debtors | 28.02 | 13.39 | 9.10 | 5.71 | 6.45 | 7.52 | 7.03 |
| Cash & bank balances | 9.29 | 5.14 | 18.58 | 1.99 | 1.61 | 3.53 | 2.58 |
| Loans & advances | 11.89 | 1.16 | 1.83 | 0.59 | 1.15 | 0.38 | 0.53 |
| Total current assets | 61.78 | 26.93 | 38.35 | 17.97 | 19.10 | 19.11 | 13.60 |
| Total current liabilities | 33.51 | 9.11 | 2.70 | 1.46 | 6.28 | 7.16 | 5.73 |
| Net working capital | 28.27 | 17.82 | 35.65 | 16.51 | 12.82 | 11.95 | 7.87 |
| Total assets | 76.54 | 69.98 | 67.78 | 18.41 | 15.37 | 20.66 | 19.03 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Opening cash | 0.52 | 2.92 | 1.99 | 1.61 | 3.53 | 2.58 | 5.20 |
| Net cash from operating activities | 1.93 | 0.96 | (2.27) | (3.06) | (2.34) | (2.13) | 1.39 |
| Net cash from investing activities | (1.64) | (2.92) | (29.03) | 0.36 | 0.42 | (1.41) | (4.01) |
| Net cash from financing activities | (0.02) | (0.44) | 47.89 | 3.08 | 0.00 | 4.50 | 0.00 |
| Net change in cash | 0.27 | (2.39) | 16.59 | 0.39 | (1.93) | 0.96 | (2.62) |
| Closing cash | 9.29 | 5.14 | 18.58 | 1.99 | 1.61 | 3.53 | 2.58 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Growth | |||||||
| Sales growth | +298.5% | +8.4% | +19.2% | -6.6% | +28.2% | +29.2% | - |
| EBITDA growth | +450.0% | +144.4% | -30.8% | +151.0% | -142.9% | +85.9% | - |
| PBT growth | +70.6% | +669.4% | +75.0% | +9998.0% | - | +25.8% | +328.6% |
| Net income growth | +121.1% | +3428.6% | -93.8% | +660.0% | -115.9% | +26.0% | - |
| Revenue CAGR (3Y) | +72.7% | +6.5% | +12.6% | +15.7% | +315.8% | +543.4% | +225.2% |
| EBITDA CAGR (3Y) | +110.1% | - | -46.7% | -25.9% | +78.3% | - | - |
| Profitability & leverage | |||||||
| Net income margin | +4.2% | +8.5% | +0.2% | +4.4% | -0.7% | +5.9% | +6.1% |
| Return on capital employed | +9.5% | +5.6% | +1.8% | +1.8% | 0.0% | +7.6% | +5.8% |
| Return on net worth | +7.8% | +4.1% | +0.1% | +6.4% | 0.0% | +6.4% | +4.9% |
| Debt / equity | 0.06 | 0.05 | 0.08 | 0.10 | 0.00 | 0.00 | 0.00 |
| Long-term debt / equity | 0.06 | 0.05 | 0.07 | 0.08 | 0.00 | 0.00 | 0.00 |
| Interest cover | 27.44 | 45.16 | 243.75 | 25.00 | 0.00 | 0.00 | 0.00 |
| Efficiency & per share | |||||||
| Fixed asset turnover | 155.44 | 106.32 | 190.06 | 176.00 | 260.19 | 355.17 | 550.00 |
| Inventory turnover | 13.25 | 4.10 | 3.28 | 2.61 | 3.11 | 3.83 | 9.54 |
| Debtors turnover | 6.34 | 2.93 | 4.11 | 4.20 | 3.91 | 2.93 | 4.67 |
| EPS (₹) | 0.10 | 0.05 | 0.00 | 0.04 | (0.01) | 0.05 | 0.05 |
| Dividend per share (₹) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Book value per share (₹) | 1.29 | 1.20 | 1.17 | 0.55 | 0.56 | 0.75 | 0.81 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Genpharmasec
Complete news archive for Genpharmasec
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Genpharmasec
Genpharmasec has 10 employees.
The primary company behind Genpharmasec, Genpharmasec Limited, reported revenue of ₹143 Cr for FY 2026, up 315% year on year.
Genpharmasec was incorporated in 1992 as a public limited company within the pharmaceutical sector. Operations are centered on the development and distribution of pharmaceutical products, with efforts directed toward expanding the product portfolio and increasing trade. The company is overseen by a team of experienced executives, including a designated Company Secretary and Compliance Officer. Focus remains on core pharmaceutical services without specified geographic limitations.
Genpharmasec offers Pharmaceutical Products and Compliance Services.
Yes, Genpharmasec is publicly traded on BSE under the ticker symbol GENPHARMA.
Genpharmasec operates through Genpharmasec Limited.
The legal entities of Genpharmasec currently have 7 directors, including Mayur Bharatbhai Bhatt, Sachin Prakash Aphandkar, Hardik Pravinbhai Makwana and others.

